PE20030043A1 - Derivados acidos de azol sustituidos utiles como agentes antidiabeticos y antiobesidad y metodo - Google Patents
Derivados acidos de azol sustituidos utiles como agentes antidiabeticos y antiobesidad y metodoInfo
- Publication number
- PE20030043A1 PE20030043A1 PE2002000455A PE2002000455A PE20030043A1 PE 20030043 A1 PE20030043 A1 PE 20030043A1 PE 2002000455 A PE2002000455 A PE 2002000455A PE 2002000455 A PE2002000455 A PE 2002000455A PE 20030043 A1 PE20030043 A1 PE 20030043A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- activator
- peroxisome
- proliferator
- azol
- Prior art date
Links
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical class C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 title abstract 2
- 239000002253 acid Substances 0.000 title abstract 2
- 229940125708 antidiabetic agent Drugs 0.000 title abstract 2
- 239000003472 antidiabetic agent Substances 0.000 title abstract 2
- 230000003178 anti-diabetic effect Effects 0.000 title 1
- 239000000883 anti-obesity agent Substances 0.000 title 1
- 229940125710 antiobesity agent Drugs 0.000 title 1
- -1 AMINO Chemical class 0.000 abstract 3
- 239000012190 activator Substances 0.000 abstract 3
- 229910052799 carbon Inorganic materials 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000002148 esters Chemical class 0.000 abstract 2
- 210000002824 peroxisome Anatomy 0.000 abstract 2
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 102000014914 Carrier Proteins Human genes 0.000 abstract 1
- 108010078791 Carrier Proteins Proteins 0.000 abstract 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 abstract 1
- 101710088194 Dehydrogenase Proteins 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 101100395338 Mus musculus Hmga2 gene Proteins 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- SRBFZHDQGSBBOR-LECHCGJUSA-N alpha-D-xylose Chemical compound O[C@@H]1CO[C@H](O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-LECHCGJUSA-N 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229960001761 chlorpropamide Drugs 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 230000009977 dual effect Effects 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- 229960004580 glibenclamide Drugs 0.000 abstract 1
- 229960000346 gliclazide Drugs 0.000 abstract 1
- 229960004346 glimepiride Drugs 0.000 abstract 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 abstract 1
- 229960001381 glipizide Drugs 0.000 abstract 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 206010024627 liposarcoma Diseases 0.000 abstract 1
- 229960003105 metformin Drugs 0.000 abstract 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000003614 peroxisome proliferator Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 150000003626 triacylglycerols Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29438001P | 2001-05-30 | 2001-05-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20030043A1 true PE20030043A1 (es) | 2003-02-05 |
Family
ID=23133159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2002000455A PE20030043A1 (es) | 2001-05-30 | 2002-05-30 | Derivados acidos de azol sustituidos utiles como agentes antidiabeticos y antiobesidad y metodo |
Country Status (17)
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006500378A (ja) * | 2002-08-21 | 2006-01-05 | メルク エンド カムパニー インコーポレーテッド | 二元ＰＰＡＲα／γアゴニストとアンギオテンシンＩＩのＩ型受容体アンタゴニストを使用する併用療法 |
| EP1424070A1 (en) * | 2002-11-28 | 2004-06-02 | Fournier Laboratories Ireland Limited | Combination of a PPAR alpha agonist and metformin for decreasing the serum triglycerides |
| SE0300988D0 (sv) * | 2003-04-03 | 2003-04-03 | Astrazeneca Ab | New use |
| US7601756B2 (en) * | 2003-06-06 | 2009-10-13 | Snowden Pharmaceuticals, Llc | Method of treatment for irritable bowel syndrome |
| CA2531418A1 (en) | 2003-07-08 | 2005-01-20 | Novartis Ag | Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds |
| JP4661595B2 (ja) * | 2003-09-22 | 2011-03-30 | 小野薬品工業株式会社 | フェニル酢酸誘導体、その製造方法および用途 |
| JP2007526309A (ja) * | 2004-03-02 | 2007-09-13 | アベール ファーマシューティカルズ インコーポレイテッド | 生物活性剤の混合製剤またはキット |
| WO2005118166A2 (en) | 2004-06-04 | 2005-12-15 | Teva Pharmaceutical Industries, Ltd. | Pharmaceutical composition containing irbesartan |
| CN1304393C (zh) * | 2004-07-01 | 2007-03-14 | 中国药科大学 | 取代的吡唑啉酮衍生物及其制备方法与药用组合物 |
| WO2006057505A1 (en) * | 2004-11-25 | 2006-06-01 | Lg Life Sciences, Ltd. | NOVEL COMPOUNDS AS AGONIST FOR PPARϜ AND PPARα, METHOD FOR PREPARATION OF THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME |
| WO2006057503A1 (en) * | 2004-11-25 | 2006-06-01 | Lg Life Sciences, Ltd. | NOVEL COMPOUNDS AS AGONIST FOR PPARϜ AND PPARα, METHOD FOR PREPARATION OF THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME |
| WO2007058504A1 (en) * | 2005-11-21 | 2007-05-24 | Lg Life Sciences, Ltd. | Novel compounds as agonist for ppar gamma and ppar alpha, method for preparation of the same, and pharmaceutical composition containing the same |
| WO2008127813A1 (en) * | 2007-03-09 | 2008-10-23 | Hiberna Corporation | Hibernation-related genes and proteins, activators and inhibitors thereof and methods of use |
| EP2211856A4 (en) * | 2007-11-29 | 2011-02-09 | Hospital For Sick Children | COMPOSITIONS AND METHODS FOR TREATING LYSOSOMAL DISORDER |
| CA2742007C (en) * | 2008-10-29 | 2014-07-08 | Deciphera Pharmaceuticals, Llc | Cyclopropane amides and analogs exhibiting anti-cancer and anti-proliferative activities |
| AU2019387370A1 (en) | 2018-11-30 | 2021-06-10 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| CN109498622A (zh) * | 2018-12-28 | 2019-03-22 | 成都恒瑞制药有限公司 | 一种氯沙坦钾与罗格列酮组合物及其制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1003445B (zh) * | 1984-10-03 | 1989-03-01 | 武田药品工业株式会社 | 噻唑烷二酮衍生物，其制备方法和用途 |
| US5591862A (en) * | 1993-06-11 | 1997-01-07 | Takeda Chemical Industries, Ltd. | Tetrazole derivatives, their production and use |
| NZ515087A (en) * | 1999-04-28 | 2003-11-28 | Aventis Pharma Gmbh | Tri-aryl acid derivatives as PPAR receptor ligands |
| EP1210345B1 (en) * | 1999-09-08 | 2004-03-03 | Glaxo Group Limited | Oxazole ppar antagonists |
| CA2390923A1 (en) * | 1999-11-10 | 2001-05-31 | Takeda Chemical Industries, Ltd. | 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity |
| EP1394154A4 (en) * | 2001-03-23 | 2005-05-18 | Takeda Pharmaceutical | FIVE-GLASS HETEROCYCLIC ALKANIC ACID DERIVATIVE |
-
2002
- 2002-05-22 US US10/153,454 patent/US20030092736A1/en not_active Abandoned
- 2002-05-23 DE DE0001390363T patent/DE02729306T1/de active Pending
- 2002-05-23 WO PCT/US2002/016633 patent/WO2002096358A2/en not_active Ceased
- 2002-05-23 TR TR2004/00650T patent/TR200400650T3/xx unknown
- 2002-05-23 HU HU0401504A patent/HUP0401504A3/hu unknown
- 2002-05-23 AU AU2002259306A patent/AU2002259306B2/en not_active Ceased
- 2002-05-23 JP JP2002592871A patent/JP2004536070A/ja active Pending
- 2002-05-23 MX MXPA03010997A patent/MXPA03010997A/es active IP Right Grant
- 2002-05-23 PL PL02367066A patent/PL367066A1/xx not_active Application Discontinuation
- 2002-05-23 EP EP02729306A patent/EP1390363A4/en not_active Withdrawn
- 2002-05-23 CZ CZ20033230A patent/CZ20033230A3/cs unknown
- 2002-05-23 CA CA002449160A patent/CA2449160A1/en not_active Abandoned
- 2002-05-23 ES ES02729306T patent/ES2214168T1/es active Pending
- 2002-05-24 TW TW091111100A patent/TWI235061B/zh not_active IP Right Cessation
- 2002-05-30 PE PE2002000455A patent/PE20030043A1/es not_active Application Discontinuation
- 2002-05-30 UY UY27316A patent/UY27316A1/es not_active Application Discontinuation
-
2003
- 2003-11-28 NO NO20035312A patent/NO327089B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| PL367066A1 (en) | 2005-02-21 |
| CZ20033230A3 (cs) | 2004-02-18 |
| ES2214168T1 (es) | 2004-09-16 |
| EP1390363A4 (en) | 2011-01-05 |
| TR200400650T3 (tr) | 2004-06-21 |
| NO20035312D0 (no) | 2003-11-28 |
| US20030092736A1 (en) | 2003-05-15 |
| AU2002259306B2 (en) | 2007-02-08 |
| WO2002096358A2 (en) | 2002-12-05 |
| EP1390363A2 (en) | 2004-02-25 |
| TWI235061B (en) | 2005-07-01 |
| MXPA03010997A (es) | 2004-02-27 |
| WO2002096358A3 (en) | 2003-03-27 |
| CA2449160A1 (en) | 2002-12-05 |
| HUP0401504A3 (en) | 2008-05-28 |
| UY27316A1 (es) | 2002-12-31 |
| HUP0401504A2 (hu) | 2004-11-29 |
| DE02729306T1 (de) | 2004-08-26 |
| JP2004536070A (ja) | 2004-12-02 |
| NO327089B1 (no) | 2009-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20091014A1 (es) | Compuestos espiro y uso farmaceutico de los mismos | |
| ES2526463T3 (es) | Exendina para el tratamiento de la diabetes y la reducción del peso corporal | |
| PE20011056A1 (es) | Acidos ariloxiaceticos para la diabetes y trastornos de los lipidos | |
| ES2039773T3 (es) | Procedimiento para preparar una preparacion farmaceutica para el tratamiento de la diabetes mellitus. | |
| ECSP034848A (es) | Derivados oxazol acido carboxilico sustituidos para uso como activadores ppar-alpha y -gamma en el tratamiento de diabetes | |
| CO6150170A2 (es) | Derivados de 1-(-d-glucopiranosil)-3-(4-ciclopropilfenilmetil)-4-halogeno indol y uso de los mismos como inhibidores de los transportadores de glucosa dependientes de sodio | |
| CN1344168A (zh) | 眼用组合物 | |
| WO2001012187A3 (en) | Benzoic acid derivatives and their use as ppar receptor agonists | |
| PE20040655A1 (es) | Nuevos derivados de glicosido de tiofeno, procedimientos para su preparacion y medicamentos que los contienen | |
| RU2005141226A (ru) | Конкретное глюкокортикостероидное соединение, обладающее противовоспалительной активностью | |
| PA8562801A1 (es) | Nuevos derivados de pirido (2,1-a) isoquinolina | |
| PE20030989A1 (es) | Derivados de tiazol y oxazol que modulan la actividad de ppar | |
| ES2137260T3 (es) | Composicion farmaceutica para uso en el tratamiento del glaucoma. | |
| PE20100733A1 (es) | Derivados de tiadiazolidinona como inhibidores de ptpasas | |
| ES2153820T3 (es) | Derivados de benzimidazol, procedimiento para su preparacion y aplicaciones. | |
| MX9400037A (es) | Composicion oftalmica para el tratamiento de glaucoma e hipertension ocular. | |
| AR032138A1 (es) | Derivados de 6-hidroxi-indazol, una composicion oftalmica, y el uso de dichos derivados para la manufactura de un medicamento para el tratamiento de glaucoma | |
| NO890529D0 (no) | Oksazolidin-2-on-derivater som hypoglycemiske midler. | |
| UY29802A1 (es) | Análogos de la feniletilamina y su uso en el tratamiento del glaucoma | |
| CL2004000512A1 (es) | Compuestos derivados del acido 3-{1-(3-(1,3-benzotiazol-6-il) propilcarbamoil]cicloalquil}propanoico, inhibidores de endopeptidasa neutra; composicion farmaceutica que los comprende; y su uso para tratar hipertension, insuficiencia cardiaca, diabetes | |
| PE20020173A1 (es) | Uso de uno o mas antagonistas de aldosterona para el tratamiento o profilaxis de enfermedades mediadas por aldosterona | |
| ES8602716A1 (es) | Procedimiento para la preparacion de derivados de tiazolidina. | |
| RU2007139928A (ru) | Производное бензимидазола и применение в качестве антагониста ангиотензина | |
| PE20061446A1 (es) | Compuestos de bencimidazol-carboxamida como agonistas de receptores 5-ht4 | |
| AR051797A1 (es) | Derivados de hidantoina inhibidores de metaloproteinasas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |